Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Progressive multifocal leukoencephalopathy in transplant recipients.

Mateen FJ, Muralidharan R, Carone M, van de Beek D, Harrison DM, Aksamit AJ, Gould MS, Clifford DB, Nath A.

Ann Neurol. 2011 Aug;70(2):305-22. doi: 10.1002/ana.22408.

2.

Progressive multifocal leukoencephalopathy in transplant recipients.

Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR.

Transpl Int. 2005 Jan;17(11):658-65. Epub 2004 Dec 23. Review.

3.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

4.

Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death.

Wyen C, Hoffmann C, Schmeisser N, Wöhrmann A, Qurishi N, Rockstroh J, Esser S, Rieke A, Ross B, Lorenzen T, Schmitz K, Stenzel W, Salzberger B, Fätkenheuer G.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1263-8.

PMID:
15385733
5.

Incidence of progressive multifocal leukoencephalopathy in patients without HIV.

Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J.

Neurology. 2010 Oct 12;75(15):1326-32. doi: 10.1212/WNL.0b013e3181f73600.

PMID:
20938025
6.

Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.

Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, Gerevini S, Bestetti A, Pedale R, Sala S, Sala S, Lazzarin A, Cinque P.

Clin Infect Dis. 2005 Mar 1;40(5):738-44. Epub 2005 Feb 1.

PMID:
15714422
7.

Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.

Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, Pedersen C, Mogensen CB, Nielsen L, Obel N.

J Infect Dis. 2009 Jan 1;199(1):77-83. doi: 10.1086/595299.

PMID:
19007313
8.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
9.

Progressive multifocal leukoencephalopathy in a lung transplant recipient.

Shitrit D, Nirit L, Shiran SI, Izbicki G, Sofer D, Eldad M, Kramer MR.

J Heart Lung Transplant. 2003 Aug;22(8):946-50.

PMID:
12909477
10.

Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy.

Sainz-de-la-Maza S, Casado JL, Pérez-Elías MJ, Moreno A, Quereda C, Moreno S, Corral I.

Eur J Neurol. 2016 May;23(5):919-25. doi: 10.1111/ene.12963. Epub 2016 Feb 23.

PMID:
26914970
11.

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.

Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME.

J Autoimmun. 2008 Feb-Mar;30(1-2):90-8. doi: 10.1016/j.jaut.2007.11.013. Review.

PMID:
18191544
12.

Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy.

Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Mertenskötter T, Eggers C, Stellbrink HJ.

AIDS. 1998 Jul 9;12(10):1149-54.

PMID:
9677163
13.

Determinants of survival in progressive multifocal leukoencephalopathy.

Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ.

Neurology. 2009 Nov 10;73(19):1551-8. doi: 10.1212/WNL.0b013e3181c0d4a1. Erratum in: Neurology. 2012 Jan 24;78(4):294.

14.

Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan.

Nakamichi K, Mizusawa H, Yamada M, Kishida S, Miura Y, Shimokawa T, Takasaki T, Lim CK, Kurane I, Saijo M.

BMC Neurol. 2012 Oct 15;12:121. doi: 10.1186/1471-2377-12-121.

15.

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Baldwin KJ, Hogg JP.

Curr Opin Neurol. 2013 Jun;26(3):318-23. doi: 10.1097/WCO.0b013e328360279f. Review.

PMID:
23493158
16.

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

Berger JR, Houff S.

Neurol Res. 2006 Apr;28(3):299-305. Review.

PMID:
16687057
17.

Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Sidhu N, McCutchan JA.

J Neuroimmunol. 2010 Feb 26;219(1-2):100-4. doi: 10.1016/j.jneuroim.2009.11.013. Epub 2009 Dec 4.

18.

Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy.

Marzocchetti A, Cingolani A, Giambenedetto SD, Ammassari A, Giancola ML, Cauda R, Antinori A, Luca AD.

J Neurovirol. 2005 Apr;11(2):219-24.

PMID:
16036800
19.

Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine.

Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, Sève P.

Clin Drug Investig. 2016 Oct;36(10):783-9. doi: 10.1007/s40261-016-0433-8. Review.

PMID:
27401779
20.

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O.

Ann Neurol. 2014 Dec;76(6):792-801. doi: 10.1002/ana.24153. Epub 2014 May 8.

Supplemental Content

Support Center